



TriMark Publications

September 2018
Volume: TMRPOC18-0901

**POINT OF CARE
DIAGNOSTIC TESTING
WORLD MARKETS**
(SAMPLE COPY, NOT FOR RESALE)

Trends, Industry Participants, Product Overviews and Market Drivers

TABLE OF CONTENTS

1.	Overview	18
1.1	About This Report	18
1.2	Scope of the Report	20
1.3	Objectives	20
1.4	Methodology	20
1.5	Executive Summary	22
2.	Overview of Diagnostic Testing Point of Care Markets	26
2.1	Key Issues in the POC Diagnostic Testing Sector	31
2.1.1	Current Market Trends and Drivers	31
2.1.2	Effectiveness of POCT	32
2.1.3	New Growth Areas for POCT	33
2.1.4	Advantages of POCT in a Clinical Setting	33
2.1.5	Pricing and Reimbursement Issues	34
2.1.6	Key Customer Segments	34
2.2	Global Point of Care Marketplace	34
2.3	Shifts from Central Lab Testing to POCT	35
2.4	Geographical Distribution	36
2.5	Challenges of POCT	39
2.6	Key Issues for POCT	39
2.6.1	Locations of POCT	39
2.6.2	Milestones in Technology Development	41
2.6.3	Drive for Decentralization from Lab	41
2.6.4	Competitive Landscape for POCT	42
2.7	The Future of POCT	43
3.	Summary Analysis of the Global POCT Market: Value, Growth Rates and Market Share	45
3.1	Global POCT Market	45
3.2	Global Market Revenues Analysis by Market Segment	46
3.2.1	Global POC Blood Glucose Monitoring Systems Market	46
3.2.2	Global POC Blood Gas and Electrolyte Analyzers Market	47
3.2.3	Global POC Rapid Coagulation Analyzers Market	47
3.2.4	Global POC Cardiac Markers Devices Market	48
3.2.5	Global POC Substance Abuse Testing Device Market	49
3.2.6	Global POC Infectious Disease Testing Device Market	49
3.2.7	Global POC Urine Strip Testing Market	49
3.2.8	Global POC Pregnancy Testing Device Market	50
3.2.9	Global POC Fecal Occult Device Market	51
3.2.10	Global POC Cholesterol Testing Market	51
3.3	Global Market Share Analysis	52
3.4	Global Market Size by Geographic Location	52
4.	Analysis of the U.S. POCT Market: Value, Growth Rates and Market Share	54
4.1	U.S. Market Revenues Analysis by Market Segment	54
4.1.1	U.S. POC Blood Glucose Monitoring Systems Market	54
4.1.2	U.S. POC Blood Gas and Electrolyte Analyzers Market	55
4.1.3	U.S. POC Rapid Coagulation Analyzers Market	56
4.1.4	U.S. POC Cardiac Markers Devices Market	56
4.1.5	U.S. POC Substance Abuse Testing Device Market	57
4.1.6	U.S. POC Infectious Disease Testing Device Market	57
4.1.7	U.S. POC Urine Strip Testing Market	58
4.1.8	U.S. POC Pregnancy Testing Device Market	58
4.1.9	U.S. POC Fecal Occult Device Market	59
4.1.10	U.S. POC Cholesterol Testing Market	59

4.2	U.S. Market Share Analysis	60	
4.3	U.S. Market Size by Analyte Market Segment	61	
5.	Analysis of the European POCT Market: Value, Growth Rates and Market Shares		62
5.1	European Market Revenues Analysis	68	
5.2	European Market Revenues Analysis by Geographic Region	69	
5.2.1	French Revenues for POCT Systems	69	
5.2.2	German Revenues for POCT Systems	70	
5.2.3	Italian Revenues for POCT Systems	70	
5.2.4	Spanish Revenues for POCT Systems	71	
5.2.5	U.K. Revenues for POCT Systems	71	
5.2.6	Benelux Revenues for POCT Systems	72	
5.2.7	Scandinavian Revenues for POCT Systems	72	
5.2.8	Rest of Europe Revenues for POCT Systems	73	
5.3	European Market Revenues Analysis by Market Segment	73	
5.3.1	European POC Blood Glucose Monitoring Systems Market	73	
5.3.2	European POC Blood Gas and Electrolyte Analyzers Market	74	
5.3.3	European POC Rapid Coagulation Analyzers Market	75	
5.3.4	European POC Cardiac Marker Market	75	
5.3.5	European POC Substance Abuse Testing Device Market	77	
5.3.6	European POC Infectious Disease Testing Market	78	
5.3.7	European POC Urine Strip Testing Market	78	
5.3.8	European POC Pregnancy Testing Device Market	79	
5.3.9	European POC Fecal Occult Blood Testing Market	79	
5.3.10	European POC Cholesterol Testing Market	80	
5.4	European Market Share Analysis	81	
6.	Analysis of the POCT Markets for Japan, China and India: Value, Growth Rates and Market Share		82
6.1	Summary Analysis of Japanese, Chinese and Indian POCT Market Revenues	82	
6.2	Summary of Asian (Japanese, Chinese and Indian) Market Revenues by Market Segment		83
6.2.1	Asian (Japanese, Chinese and Indian) POC Blood Glucose Monitoring Systems Market	83	
6.2.2	Asian (Japanese, Chinese and Indian) POC Blood Gas and Electrolyte Analyzers Market		83
6.2.3	Asian (Japanese, Chinese and Indian) POC Rapid Coagulation Analyzers Market	84	
6.2.4	Asian (Japanese, Chinese and Indian) POC Cardiac Markers Devices Market	84	
6.2.5	Asian (Japanese, Chinese and Indian) POC Substance Abuse Testing Device Market	85	
6.2.6	Asian (Japanese, Chinese and Indian) POC Infectious Disease Testing Device Market	85	
6.2.7	Asian (Japanese, Chinese and Indian) POC Urine Strip Testing Market	86	
6.2.8	Asian (Japanese, Chinese and Indian) POC Pregnancy Testing Device Market	86	
6.2.9	Asian (Japanese, Chinese and Indian) POC Fecal Occult Device Market	87	
6.2.10	Asian (Japanese, Chinese and Indian) POC Cholesterol Testing Market	87	
6.3	Asian (Japanese, Chinese and Indian) Market Share Analysis	88	
6.4	Summary Analysis of the Japanese POCT Market	88	
6.5	Summary Analysis of the Indian POCT Market	91	
6.6	Summary Analysis of the Chinese POCT Market	94	
7.	Analysis of the Rest of World (ROW) POCT Market: Value, Growth Rates and Market Share		101
7.1	Summary Analysis of the ROW POCT Market Revenues	101	
7.2	Summary of the ROW Market Revenues by Market Segment		102
7.2.1	ROW POC Blood Glucose Monitoring Systems Market	102	
7.2.2	ROW POC Blood Gas and Electrolyte Analyzers Market	102	
7.2.3	ROW POC Rapid Coagulation Analyzers Market	103	
7.2.4	ROW POC Cardiac Markers Devices Market	103	
7.2.5	ROW POC Substance Abuse Testing Device Market	104	
7.2.6	ROW POC Infectious Disease Testing Device Market	105	
7.2.7	ROW POC Urine Strip Testing Market	105	

7.2.8	ROW POC Pregnancy Testing Device Market	106	
7.2.9	ROW POC Fecal Occult Device Market	106	
7.2.10	ROW POC Cholesterol Testing Market	107	
7.3	ROW Market Share Analysis	107	
7.4	Summary Analysis of the ROW POCT Market Revenues	108	
7.4.1	Summary Analysis of the Argentinian POCT Market	108	
7.4.2	Summary Analysis of the Australian POCT Market	108	
7.4.3	Summary Analysis of the Brazilian POCT Market	109	
7.4.4	Summary Analysis of the Canadian POCT Market	109	
7.4.5	Summary Analysis of the Russian POCT Market	110	
7.4.6	Summary Analysis of the Middle East POCT Market	111	
7.4.7	Summary Analysis of the African POCT Market	112	
7.4.8	Summary Analysis of the Asia-Pacific POCT Market	113	
8.	Review of the Market Segments, Reagents and Equipment	117	
8.1	Blood Glucose Monitoring	117	
8.1.1	Introduction to Blood Glucose Monitoring	117	
8.1.2	Types of Blood Glucose Testing	118	
8.1.2.1	Fasting Blood Sugar (FBS) or Fasting Plasma Glucose (FPG)	118	118
8.1.2.2	Two-Hour Postprandial Blood Sugar or Two-Hour PC	118	118
8.1.2.3	Random Blood Sugar (RBS)	118	
8.1.2.4	Glucose Urine Test	118	
8.1.2.5	Blood Glucose Test Strip	118	
8.1.2.6	Glycosylated Hemoglobin (HbA1c)	119	
8.1.2.7	Intravenous Glucose Tolerance Test (IVGTT)	119	
8.1.2.8	Oral Glucose Tolerance Test (OGTT)	119	
8.1.3	Segmentation of POC Blood Glucose Testing	119	
8.1.3.1	Continuous Blood Glucose Monitoring (CBGM)	119	
8.1.3.2	Self-Monitoring Blood Glucose (SMBG) Testing	121	
8.1.3.3	Minimally-Invasive and Non-Invasive Blood Glucose Testing	121	121
8.1.3.4	Emerging Glucose Monitoring Technologies	122	
8.1.3.5	Optical Transducer Technologies	122	
8.1.3.6	Transdermal Sensor Technologies	123	
8.1.3.7	Invasive Glucose Sensor Technologies	123	
8.1.4	Review of Professional POC Blood Glucose Monitoring Systems	124	
8.1.4.1	New Guidance: Use of Blood Glucose Monitoring Systems for Professional and Home POC	124	124
8.1.5	Review of POC Blood Glucose Monitoring Products	125	
8.1.5.1	Abaxis, Inc.	127	
8.1.5.2	Abbott	127	
8.1.5.3	Alere	128	
8.1.5.4	Apex Biotechnology	129	
8.1.5.5	ARKRAY, Inc.	129	
8.1.5.6	EKF Diagnostics	130	
8.1.5.7	Fora Care	130	
8.1.5.8	HemoCue (part of Radiometer)	130	
8.1.5.9	HMD BioMedical	131	
8.1.5.10	Jant Pharmacal	131	
8.1.5.11	LifeHealth (formerly International Technidyne Corp.)	132	132
8.1.5.12	Medtronic	132	
8.1.5.13	Nova Biomedical	132	
8.1.5.14	Polymer Technology Systems	133	
8.1.5.15	Roche	133	
8.1.5.16	Siemens	134	
8.1.6	Professional POC Hemoglobin A1c (HbA1c) Testing	135	
8.1.6.1	A. Menarini Diagnostics	135	
8.1.6.2	Alere	136	

8.1.6.3	Apex Biotechnology	136	
8.1.6.4	Convergent Technologies GmbH & Co.	136	
8.1.6.5	DiaSys Diagnostic Systems	136	
8.1.6.6	Diazyme Laboratories	137	
8.1.6.7	EKF Diagnostics	137	
8.1.6.8	Erba Mannheim	137	
8.1.6.9	Eurolyser	138	
8.1.6.10	Green Cross Medis (formerly Ceragem Medisys)	138	
8.1.6.11	HemoCue (a division of Radiometer)	138	
8.1.6.12	Roche	138	
8.1.6.13	SD Biosensor	139	
8.1.6.14	Siemens Healthcare Diagnostics	139	
8.1.7	Market Analysis	139	
8.1.7.1	Worldwide Professional Glucose Testing Market	141	
8.1.7.2	U.S. Professional Glucose Testing Market	141	
8.1.8	Competitive Analysis for the Glucose POCT Sector	142	
8.1.9	Market Share for Glucose Testing	144	
8.1.10	Competitive Analysis for the Glucose POCT Sector	144	
8.1.11	Market Analysis	145	
8.1.11.1	Market Drivers	145	
8.1.11.2	Market Restraints	145	
8.1.12	POC Glucose Testing Assay Market and Technology Trends	146	
8.1.12.1	POC Glucose Testing Assay Market Trends	146	
8.1.12.2	POC Glucose Testing Assay Technology Trends	146	
8.1.12.3	POC Glucose Testing Assay Strategic Recommendations	146	
8.2	Blood Gas and Electrolytes	147	
8.2.1	Background to POC Blood Gas and Electrolyte Testing	147	
8.2.1.1	Acid-Base Balance and the Lungs	148	
8.2.1.2	Respiratory Acidosis	148	
8.2.1.3	Respiratory Alkalosis	148	
8.2.1.4	Metabolic (or Non-Respiratory) Acidosis	148	
8.2.1.5	Metabolic (or Non-Respiratory) Alkalosis	149	
8.2.1.6	Increasing Popularity of POC Blood Gas and Electrolyte Testing	149	
8.2.2	Market Segmentation (Segmentation by Type of Blood Gas Monitoring Equipment)	149	
8.2.2.1	Intermittent Blood Gas Monitoring Equipment	149	
8.2.2.2	Continuous Blood Gas Monitoring Equipment	150	
8.2.2.3	EABG Monitors	150	
8.2.2.4	IABG Monitors	150	
8.2.2.5	Portable Blood Gas Analyzers	151	
8.2.2.6	Next Generation Blood Gas Analyzers	151	
8.2.3	Applications for POCT Blood Gas and Electrolyte Analyzers	151	
8.2.4	Emerging Technologies	151	
8.2.5	Whole-Blood Lactate	152	
8.2.6	Creatinine	152	
8.2.7	Electrolytes Point of Care Analysis: Comparison of POCT and Central Lab Results	153	
8.2.8	Review of Selected Blood Gas and Electrolyte Analyzers	154	
8.2.9	Review of Company Products	156	
8.2.9.1	Roche Corporation	156	
8.2.9.2	Siemens Healthcare Diagnostics	156	
8.2.9.3	Instrumentation Laboratory	157	
8.2.9.4	Nova Biomedical	158	
8.2.9.5	Radiometer	158	
8.2.9.6	Abbott Point of Care	159	
8.2.9.7	Accriva Diagnostics	160	
8.2.9.8	Alere	160	
8.2.9.9	Opti Medical	160	

8.2.9.10	LifeHealth	160	
8.2.10	Terumo	160	
8.2.11	Market Share for Blood Gas and Electrolyte Testing		161
8.2.12	Market Analysis	161	
8.2.12.1	Market Drivers	161	
8.2.12.2	Market Restraints	162	
8.2.13	POC Blood Gas and Electrolyte Testing Assay Market and Technology Trends		163
8.2.13.1	POC Blood Gas and Electrolyte Testing Assay Market Trends	163	
8.2.13.2	POC Blood Gas and Electrolyte Testing Assay Technology Trends	163	
8.2.13.3	POC Blood Gas and Electrolyte Testing Assay Strategic Recommendations		163
8.3	Rapid Coagulation Tests	164	
8.3.1	Background to Rapid Coagulation Tests	165	
8.3.2	Review of Selected POC Rapid Coagulation Analyzers		171
8.3.3	Review of Company Products	173	
8.3.3.1	Roche Diagnostics Corp.	173	
8.3.3.2	Abbott Laboratories	174	
8.3.3.3	Accriva	175	
8.3.3.4	Medtronic	176	
8.3.3.5	Alere	176	
8.3.3.6	Helena Laboratories Point of Care		177
8.3.3.7	Hemonetics	179	
8.3.3.8	Sienco, Inc.	179	
8.3.3.9	Instrumentation Laboratory's GEM PCL Plus		180
8.3.4	Connectivity Issues	181	
8.3.5	Cost Benefits	181	
8.3.6	Quality Control Issues	182	
8.3.7	Certification for POC Coagulation Devices		182
8.3.8	D-Dimer Testing	183	
8.3.9	Market Analysis	183	
8.3.9.1	Market Share for POCT Coagulation Testing		183
8.3.9.2	Competitive Analysis of Sector Companies		184
8.3.9.3	Market Drivers	184	
8.3.9.4	Market Restraints	185	
8.3.9.5	POC Coagulation Testing Assay Market Trends	186	
8.3.9.6	POC Coagulation Testing Assay Technology Trends		186
8.3.9.7	POC Coagulation Testing Assay Strategic Recommendations		186
8.3.9.8	SWOT Analysis: Summary of Strengths, Weaknesses, Opportunities and Threats in the Coagulation POC Market	187	
8.4	POC Rapid Cardiac Markers	187	
8.4.1	Background to POC Rapid Cardiac Marker Testing		188
8.4.2	Cardiac Marker Tests	189	
8.4.2.1	Creatine Kinase (CK)	189	
8.4.2.2	Myoglobin	190	
8.4.2.3	Cardiac Troponins T (TnT), I (TnI) and C (TnC)		191
8.4.2.4	C-Reactive Protein (CRP)	192	
8.4.2.5	Homocysteine	193	
8.4.3	Emerging Markers	194	
8.4.3.1	B-Type Natriuretic Peptide (BNP)		194
8.4.3.2	Myeloperoxidase (MPO)	195	
8.4.3.3	Ischemia-Modified Albumin (IMA)	195	
8.4.3.4	Glycogen Phosphorylase Isoenzyme BB (GPBB)		196
8.4.3.5	Fatty Acid-Binding Proteins (FABPs)	196	
8.4.4	Review of Selected POC Cardiac Biomarker Analyzers		196
8.4.5	Review of Company Products	198	
8.4.5.1	Abbott's i-STAT System	198	
8.4.5.2	Alere's Triage System	198	

8.4.5.3	Alpha Scientific	200	
8.4.5.4	Boditech Med's i-CHROMA D System	200	
8.4.5.5	BTNX	200	
8.4.5.6	Homemed	201	
8.4.5.7	LSI Medience (formerly Mitsubishi Chemical Medience Corp.)		201
8.4.5.8	Nano-Ditech	201	
8.4.5.9	Princeton BioMeditech	201	
8.4.5.10	Radiometer (part of Danaher)	202	
8.4.5.11	Response Biomedical Corporation		202
8.4.5.12	Roche Diagnostics	203	
8.4.5.13	Siemens Healthcare Diagnostics	204	
8.4.5.14	Trinity Biotech	205	
8.4.5.15	Trivitron Healthcare (formerly Ani Biotech)		205
8.4.5.16	bioMérieux	205	
8.4.6	Market Share and Sales for Cardiac Marker Testing		206
8.4.6.1	Market Drivers	207	
8.4.6.2	Market Restraints	208	
8.4.7	POC Cardiac Marker Testing Assay Market and Technology Trends		209
8.4.7.1	POC Cardiac Marker Testing Assay Market Trends	209	
8.4.7.2	POC Cardiac Marker Testing Assay Technology Trends	210	
8.4.7.3	POC Cardiac Marker Testing Assay Strategic Recommendations		210
8.5	POCT Substance Abuse Testing	211	
8.5.1	Background to POC Substance Abuse Testing		211
8.5.2	Substance Abuse Test Types	218	
8.5.2.1	Urine Substance/Drug Screening	218	
8.5.2.2	Hair Tests for Substance Abuse and Screening	218	
8.5.2.3	Blood Tests for Substance Abuse and Screening	219	
8.5.2.4	Saliva Tests for Substance Abuse and Screening	219	
8.5.2.5	Sweat Tests for Substance Abuse and Screening	219	
8.5.3	Alcohol Abuse and Screening	219	
8.5.4	Saliva Testing	220	
8.5.5	Qualitative Analysis	221	
8.5.5.1	Market Drivers	221	
8.5.5.2	Market Restraints	221	
8.5.6	Review of Selected POC Substance Abuse Analyzers		221
8.5.7	Review of Company Products	223	
8.5.7.1	Akers Biosciences	223	
8.5.7.2	Alere	223	
8.5.7.3	BTNX, Inc.	225	
8.5.7.4	BioScan Screening Systems, Inc.	226	
8.5.7.5	American Bio Medica Corp.	226	
8.5.7.6	OraSure	228	
8.5.7.7	Noble Medical, Inc.	229	
8.5.7.8	Pathtech	229	
8.5.7.9	Alfa Scientific Designs, Inc.	229	
8.5.7.10	Biophor Diagnostics	230	
8.5.7.11	Randox Laboratories	231	
8.5.7.12	LifeSign	231	
8.5.7.13	Princeton BioMeditech Corporation (PBM)		231
8.5.7.14	Rapid Test Pty, Ltd.	231	
8.5.7.15	Siemens Medical Solutions USA	231	
8.6	POC Pregnancy and Fertility Tests	232	
8.6.1	Background to POC Pregnancy and Fertility Tests		232
8.6.2	Review of Selected POC Pregnancy Testing Devices		232
8.6.3	Review of Company Products	233	
8.6.3.1	Quidel	233	

8.6.3.2	Alere	233	
8.6.3.3	Sutherland Health Group Ltd.	234	
8.6.3.4	Sekisui Diagnostics, LLC	234	
8.6.3.5	Siemens Diagnostics	234	
8.6.3.6	LifeSign	234	
8.6.3.7	Other Companies in this Sector	235	
8.6.3.8	Market Analysis	235	
8.6.3.8.1	Competitive Sector Analysis	235	
8.7	Fecal Occult Blood	236	
8.7.1	Background to POC Fecal Occult Blood Testing	236	
8.7.2	Review of Selected POC Fecal Occult Testing Devices	238	
8.7.3	Review of Company Products	239	
8.7.3.1	Helena Laboratories	239	
8.7.3.2	Biomerica	240	
8.7.3.3	Beckman Coulter	240	
8.7.3.4	Worldwide Medical	240	
8.7.3.5	Aerscher Diagnostics	240	
8.7.3.6	Enterix	241	
8.7.3.7	Medix Biochemica	241	
8.7.3.8	Orion Diagnostica	241	
8.7.3.9	ACON Laboratories' Mission FOB Reagent Strips	241	
8.7.3.10	Alere's Products	242	
8.7.3.12	Princeton BioMeditech's BioSign iFOBTest	242	
8.7.3.13	Quest Diagnostics' InSure FIT	242	
8.7.3.14	Quidel's QuickVue iFOB	242	
8.7.3.15	Exact Sciences' Cologuard	242	
8.7.3.16	Epigenomics	243	
8.7.3.17	CTK Biotech	243	
8.7.5	Market Analysis	243	
8.7.5.1	Market Drivers	243	
8.7.5.2	Market Restraints	244	
8.7.5.3	POC Fecal Occult Blood Testing Assay Market and Technology Trends	244	
8.7.5.3.1	POC Fecal Occult Blood Testing Assay Market Trends	244	
8.7.5.3.2	Fecal Occult Blood Testing Assay Technology Trends	244	
8.7.5.3.3	POC Fecal Occult Blood Testing Assay Strategic Recommendations	244	
8.8	POC Infectious Disease Testing	245	
8.8.1	Background to POC Infectious Disease Testing	245	
8.8.2	Types of Diagnosis for Infectious Diseases	246	
8.8.2.1	Microbial Culture	246	
8.8.2.2	Microscopy	246	
8.8.2.3	Biochemical Tests	247	
8.8.2.4	Immunologic Tests	247	
8.8.2.5	Molecular Diagnostics Testing	247	
8.8.3	Diagnostic Platforms for Infectious Diseases	248	
8.8.3.1	Centralized Laboratory Testing for Infectious Diseases	248	
8.8.3.2	POC Testing for Infectious Diseases	248	
8.8.4	Emerging Technologies	249	
8.8.5	Market Analysis	249	
8.8.5.1	Market Drivers	250	
8.8.5.2	Market Restraints	250	
8.8.6	Review of Selected POC Infectious Disease Testing Devices	250	
8.8.6.1	POC Infectious Disease Testing Devices and Assays in Development	253	
8.8.6.1.1	Cepheid's GeneXpert Omni	253	
8.8.6.1.2	Alere q	253	
8.8.6.1.3	Roche's cobas Liat System	253	
8.8.6.1.4	QuantuMDx's Q-POC	253	

8.8.6.1.5	SRI International	254	
8.8.6.1.6	Atlas Genetics' io System	254	
8.8.7	Overview of POC Assays for Detection of Infectious Disease		254
8.8.7.1	Anthrax and Other Bio-Threats	254	
8.8.7.2	Campylobacter	257	
8.8.7.3	<i>Clostridium difficile</i>	257	
8.8.7.4	<i>E. coli</i>	259	
8.8.7.5	Gastrointestinal Infectious Agents		259
8.8.7.5.1	Giardia and Cryptosporidium	260	
8.8.7.5.2	<i>Entamoeba histolytica</i>	260	
8.8.7.5.3	Rotavirus & Adenovirus	261	
8.8.7.5.4	Norovirus	261	
8.8.7.6	Hepatitis	262	
8.8.7.7	Herpes Simplex Virus Type-2	264	
8.8.7.8	Influenza	264	
8.8.7.9	Legionella	269	
8.8.7.10	Malaria Testing	270	
8.8.7.11	Meningitis	272	
8.8.7.12	Mononucleosis	273	
8.8.7.13	Procalcitonin (Detects Sepsis)	274	
8.8.7.14	Respiratory Tract Infections	275	
8.8.7.14.1	C-Reactive Proteins	275	
8.8.7.14.2	Pneumonia	275	
8.8.7.14.3	Respiratory Tract Panels	276	
8.8.7.15	RSV	277	
8.8.7.16	Rubella	279	
8.8.7.17	Sexually-Transmitted Diseases	279	
8.8.7.17.1	Chlamydia	279	
8.8.7.17.2	Gonorrhea Testing	280	
8.8.7.17.3	Syphilis	280	
8.8.7.18	Staphylococcus aureus and MRSA	282	
8.8.7.19	Streptococcus A Testing	282	
8.8.7.20	Tropical Diseases	285	
8.8.7.20.1	Chagas Disease	285	
8.8.7.20.2	Dengue Fever	286	
8.8.7.20.3	Ebola	287	
8.8.7.20.4	Filariasis	287	
8.8.7.20.5	Onchocerciasis	287	
8.8.7.20.6	Zika Virus	287	
8.8.7.21	Tuberculosis	287	
8.8.7.22	Typhoid	289	
8.9	POC Urine Strip Testing	289	
8.9.1	Background to POC Urine Strip Testing	289	
8.9.2	Emerging Technologies	291	
8.9.3	Review of Selected POC Urine Strip Testing Devices	292	
8.10	POC Cholesterol Testing	294	
8.10.1	POC Cholesterol Testing Market Size and Development	294	
8.10.2	Background to POC Cholesterol Testing	294	
8.10.3	POC Cholesterol Testing Devices	296	
8.10.3.1	Review of Selected POC Cholesterol Testing Devices	296	
8.10.4	Review of Company Products	297	
8.10.4.1	Cholestech (Now Alere)	297	
8.10.4.2	Polymer Technology Systems	297	
8.10.4.3	Miraculins	297	
8.10.4.4	Abaxis, Inc.	298	
8.10.5	Product Comparison of Leading Suppliers	298	

8.10.6	Launch Dates of Leading Products Worldwide	300
8.11	Miscellaneous POC Tests	301
8.11.1	Estriol	301
8.11.2	POC H. pylori Testing	301
8.11.3	Bacterial Contamination of Platelet Units	304
8.11.4	POC Vaginal Fluid pH and Vaginitis Testing	304
8.11.5	POC Cancer Testing	305
8.11.5.1	Prostate-Specific Antigen (PSA)	305
8.11.5.2	Bladder Cancer	306
8.11.5.3	Other Rapid Cancer Tests	308
8.11.6	Hemodynamic Monitoring	308
8.11.7	Heparin-Induced Thrombocytopenia (HIT)	309
8.11.8	Ruptured Fetal Membranes	310
8.11.9	Microalbumin Testing	310
8.11.10	Prenatal, Labor and Delivery Testing	310
8.11.10.1	Medix Biochemica	311
8.11.11	Respiratory Tests	311
8.12	HIV	314
8.12.1	Rapid HIV Assays	319
8.12.1.1	Alere	320
8.12.1.2	bioLytical Laboratories, Inc.	321
8.12.1.3	Bio-Rad Laboratories	321
8.12.1.4	Chembio Diagnostics	322
8.12.1.5	MedMira Laboratories, Inc.	322
8.12.1.6	OraSure Technologies	323
8.12.1.7	Trinity Biotech	323
8.12.2	Rapid HIV Assays Not Approved by the FDA (not commercially available in the U.S.)	324
8.12.2.1	Alere	324
8.12.2.2	bioMérieux	324
8.12.2.3	Bio-Rad	325
8.12.2.4	Core Diagnostics	325
8.12.2.5	CTK Biotech	325
8.12.2.6	EY Laboratories	325
8.12.2.7	Hema Diagnostics Systems	326
8.12.2.8	ImmunoScience	326
8.12.2.9	InTec Products	326
8.12.2.10	JAL Innovation	327
8.12.2.11	J Mitra & Co.	327
8.12.2.12	Premier Medical Corporation	327
8.12.2.13	Princeton BioMeditech	328
8.12.2.14	Savyon Diagnostics	328
8.12.2.15	Tulip Group	328
8.12.3	POC Viral Load Technologies of the Future	328
8.12.3.1	Cepheid	328
8.12.3.2	Roche	329
8.12.3.3	Wave 80 Biosciences	329
9.	POCT: Growth Regulators	330
9.1	Moderators of Growth	330
9.2	Personnel Acceptance	330
9.3	Key People for POCT	331
9.4	Information Management Issues	331
9.4.1	Elements of Information Management for POCT: Information-Processing Capabilities	331
9.4.2	Data Mining	332
9.4.3	Middleware	332
9.4.4	Web Portals	333

9.4.5	POCT-1A Standard	333	
9.5	Key Elements for POCT	334	
9.6	POCT and Reimbursement	334	
9.7	Effectiveness of Clinical Outcomes	336	
9.8	Rapid Near-Patient Testing in Hospitals	336	
9.9	Satellite Facilities	336	
9.10	Regionalization of Laboratory Care	337	
9.11	Requirements for POCT	338	
9.12	Locations of POC for Patient Care	339	
9.13	Benefits of POCT	340	
9.14	Cost Elements of POCT	340	
9.15	Necessary Functions in POCT	340	
9.16	Turnaround Time (TAT) for POCT	340	
9.17	Clinical Laboratory Improvement Amendments (CLIA)	341	
9.18	Sexually-Transmitted Diseases in Underdeveloped Countries	342	
9.19	Sources of Error in POC Testing	342	
10.	Business Trends in the POC Sector	344	
10.1	Sector Consolidation	344	
10.2	Diagnostic Testing Growth Trends	345	
10.2.1	Opportunities for Healthcare Stakeholders	346	
10.3	Acquisition, License Agreements, Internal Development and Partnerships	346	
10.4	Product Testing Depth in POCT	350	
10.5	Government Regulation	350	
10.5.1	U.S. Regulation	350	
10.5.1.1	Importing Medical Devices into the U.S.	352	
10.5.1.2	Exporting Medical Devices from the U.S.	353	
10.5.2	E.U. Regulation	353	
10.5.3	Japanese Regulation	356	
10.6	Post-Filing Regulations for POC Devices	358	
10.7	Exporting Unapproved POCTs	359	
10.8	Analyte-Specific Reagents (“Home-Brew” Tests)	359	
10.9	Medical Device Registration	359	
10.10	Product Labeling	360	
10.11	Punitive FDA Actions	360	
10.12	CLIA ‘88 and State Laboratory Laws	360	
10.13	Impact of Regulations on the Industry	361	
10.14	Minimizing Regulatory Barriers	362	
10.15	Waived Testing	364	
11.	Technology Platform Innovations in POCT	366	
11.1	Latest POCT Technological Platforms	366	
11.1.1	Device Miniaturization and Microfluidic Technologies	366	
11.1.2	Minimally-Invasive and Non-Invasive POCT Technologies	366	
11.1.2.1	Libre Flash Glucose Monitor and OneTouch Verio Sync Meter	367	
11.1.2.2	Echo Therapeutics	367	
11.1.3	Advances in Wireless Technologies	367	
11.1.4	Automation of POCT	367	
11.1.5	Developments in New Genomic Technologies (Genotyping, Haplotyping and Sequencing Technologies)	368	
11.1.6	Advances in Informatics Technologies	370	
11.1.7	Pharmacogenetic Testing	371	
11.1.8	Multi-Assay Technologies in POCT	371	
11.1.9	Molecular Diagnostic Technology in POCT for Infectious Disease	371	
11.2	Smart Phone Technology	372	
11.2.1	Aquila Diagnostic Systems, Inc.	372	

11.2.2	AgaMatrix	373	
11.2.3	Quick HIV and Syphilis Screening		373
11.2.4	Accu-Check Connect System	373	
11.3	QuantuMDx Handheld, Portable Low Cost Rapid Devices		374
12.	Data Management and Connectivity		375
12.1	Wireless LANs	375	
12.2	Connectivity Platforms	377	
12.2.1	Data Management Systems		378
12.2.1.1	Alere RALS System	379	
12.2.1.2	International Technidyne Corporation HEMOCHRON Signature Elite		380
12.2.1.3	Siemens Diagnostics Rapidpoint	380	
12.2.1.4	Radiometer	380	
12.2.1.5	HemoCue's DM Hemoglobin	380	
12.2.1.6	Roche Diagnostics Cobas IT	380	
12.2.1.7	Accriva	381	
12.2.2	BD.id	381	
12.2.3	Medical Implant Communications Service (MICS)		381
12.2.4	Conworx Technology	381	
12.2.5	Telcor QML	382	
12.2.6	Medasys	382	
12.2.7	NoemaLife	382	
12.2.8	Telcare	382	
12.3	Advantages of POCT Connectivity		382
12.3.1	Cost-Benefit Analysis of POCT and IT Connectivity		383
12.3.2	Hospital Network Issues	383	
13.	Corporate Profiles		385
13.1	Abaxis, Inc.	385	
13.2	Abbott Laboratories	386	
13.3	AccuBioTech Co., Ltd.	387	
13.4	Accriva Diagnostics	387	
13.5	ACON Laboratories, Inc.	388	
13.6	Acrongenomics	388	
13.7	AgaMatrix	389	
13.8	Aerscher Diagnostics, LLC		389
13.9	Akers Biosciences, Inc.	389	
13.10	Alere	390	
13.11	Alfa Scientific Designs, Inc.		393
13.12	American Bio Medica Corporation		393
13.13	Arkray, Inc.	394	
13.14	Atlas Genetics Ltd.	394	
13.15	Atonomics A/S	395	
13.16	Augurix Diagnostics Ltd.	395	
13.17	Axxin	395	
13.18	Beckman Coulter (Danaher Corporation)		395
13.19	bioLytical Laboratories	396	
13.20	Biomerica, Inc.	397	
13.21	bioMérieux	397	
13.22	Bio-Rad Laboratories, Inc.		397
13.23	BioScan Screening Systems, Inc.	398	
13.24	Calypte Biomedical Corporation	398	
13.25	Chembio Diagnostic, Inc.		398
13.26	ERBA Diagnostics, Inc.	399	
13.27	Daktari Diagnostics	399	
13.28	Dexcom	400	

13.29	Diagnostics for All	401	
13.30	Enigma Diagnostics Ltd.	402	
13.31	EY Laboratoires, Inc.	402	
13.32	Eurotrol	402	
13.33	Exalenz Bioscience	403	
13.34	GenBio	403	
13.35	Guided Therapeutics, Inc.	403	
13.36	Helena Laboratories	404	
13.37	Hema Diagnostic Systems, LLC	404	
13.38	Instrumentation Laboratory (IL)/Werfen Group	405	
13.39	Jant Pharmacal Corporation	405	
13.40	LifeSign, LLC	405	
13.41	Medix Biochemica	406	
13.42	MedMira Laboratories	406	
13.43	A. Menarini Diagnostics	406	
13.44	Micronics	406	
13.45	New Horizons Diagnostics	407	
13.46	Nova Biomedical	407	
13.47	OraSure Technologies, Inc.	408	
13.48	Orion Diagnostica	409	
13.49	Polymedco, Inc.	409	
13.50	Polymer Technology Systems, Inc.	410	
13.51	Qualigen	410	
13.52	Quest Diagnostics, Inc.	410	
13.53	Quidel Corporation	410	
13.54	Radiometer Medical	411	
13.55	Response Biomedical Corp.	411	
13.56	Roche Diagnostics	411	
13.57	Savyon Diagnostics	412	
13.58	Seegene	413	
13.59	Sekisui Diagnostics, LLC	413	
13.60	Shanghai Ruicare Medical Co., Ltd.	413	
13.61	Shenzhen Fitconn Technology Co., Ltd.	413	
13.62	Shionogi & Co., Ltd.	414	
13.63	Siemens AG	414	
13.64	Siloam Biosciences, Inc.	414	
13.65	Spectral Medical, Inc.	415	
13.66	StatSure Diagnostic Systems, Inc.	415	
13.67	One Step Detect Associates, LLC	415	
13.68	Senseonics	416	
13.69	Trinity Biotech Plc	416	
14.	POCT Sector Trends and Forecasts	417	
14.1	Home Care Analysis as Part of Near-Patient Testing	417	
14.2	Non-Traditional Collection for POCT	417	
14.3	New Systems for Critical Care and Near-Patient Testing	418	
14.4	Utility of Near-Patient Testing in Critical-Care Settings	418	
14.5	Physician's Office Market	419	
14.6	Information Management Advances	419	
14.7	Test-Ordering Patterns and Demand for POCT	419	
14.8	Demand for Emergency Department Services	420	
14.9	Move Away from the Central Laboratory	421	
14.10	Healthcare Cost Controls	422	
14.11	Competition for Services	422	
14.12	Drivers of POCT	423	
14.13	Confluence of New Technology	423	

14.14	Difficulties of Design for POC Products	423
14.15	Point of Care Compliance	423
14.16	The Biggest New Opportunities in POCT	426
15.	New Entrants to the Point of Care Market	427
15.1	Alliance International Co., Ltd.	427
15.2	Analyticon Biotechnologies AG	427
15.3	Ativa Medical Corporation	427
15.4	Aquila Diagnostic Systems, Inc.	428
15.5	ArcDia International Oyo Ltd.	428
15.6	Artron Laboratories, Inc.	428
15.7	Biocartis SA	429
15.8	BioFire Diagnostics, Inc.	429
15.9	BioMedomics	430
15.10	Biosensia Ltd.	430
15.11	Curetis AG	430
15.12	DxNA, LLC	431
15.13	Echo Therapeutics, Inc.	431
15.14	Gentag, Inc.	432
15.15	Great Basin Corporation	432
15.16	Immunexpress Group	432
15.17	Integrated Diagnostics	432
15.18	Integrity Applications	433
15.19	MBio Diagnostics, Inc.	433
15.20	Menssana Research, Inc.	433
15.21	Metaara Medical Technologies, Inc.	434
15.22	QuantuMDx Group	434
15.23	Philips Business Group EBA	434
15.24	Wave 80 Biosciences	434
15.25	Veredus Laboratories Pte Ltd.	435

INDEX OF FIGURES

Figure 2.1:	Worldwide Distribution of IVD Testing, 2016	37
Figure 2.2:	Top 13 Country IVD Testing Markets, 2016	38
Figure 2.3:	Market Share for IVD Testing by Company, 2016	39
Figure 3.1:	Total Global POCT Market, 2008-2021	46
Figure 3.2:	Worldwide Distribution of POCT, 2016	53
Figure 4.1:	U.S. Revenues for POCT Market, 2008-2021	54
Figure 4.2:	Summary of U.S. POCT Markets by Market Segment, 2016	61
Figure 5.1:	European Revenues for POCT Market, 2008-2021	69
Figure 6.1:	Summary Analysis of Japanese, Chinese and Indian POCT Market, 2008-2018	82
Figure 6.2:	Japanese Revenues for POCT Market, 2008-2018	90
Figure 6.3:	Indian Revenues for POCT Market, 2008-2018	94
Figure 6.4:	Chinese Revenues for POCT Market, 2008-2018	96
Figure 7.1:	Summary Analysis of ROW POCT Market, 2008-2021	101
Figure 7.2:	Summary Analysis of Russian Revenues for POCT Products Market, 2008-2018	111
Figure 7.3:	Summary Analysis of Middle East Revenues for POCT Products Market, 2008-2018	112
Figure 7.4:	Summary Analysis of African Revenues for POCT Products Market, 2008-2018	113
Figure 7.5:	Summary Analysis of Latin America Revenues for POCT Products Market, 2008-2018	116
Figure 8.1:	Global Share of Glucose Testing Market by Company, 2016	144
Figure 8.2:	Global POCT Share of Blood Gas and Electrolyte Testing Market, 2017	161
Figure 8.3:	Global POCT Share of Coagulation Testing Market, 2016	183
Figure 8.4:	Global POCT Share of Cardiac Marker Testing Market, 2016	206
Figure 8.5:	Distribution of Infectious Diseases Tested at the Point of Care	250

Figure 8.6: Incidence of Pathogens in Respiratory Specimens	312
Figure 8.7: Global POCT Share of HIV Testing Market, 2016	318
Figure 10.1: Conformity Assessment Route, Annexes and Quality System Standards by IVD Device Category	354
Figure 12.1: The Alere RALS Data Management System Connects to Most of the Major Instruments Used in Point of Care	379

INDEX OF TABLES

Table 2.1: Summary of Global Professional POCT Markets by Major Market Sub-Segment, 2016 and 2021	26
Table 2.2: Summary of U.S. Professional POCT Markets by Major Market Sub-Segment, 2016 and 2021	26
Table 2.3: Summary of European Professional POCT Markets by Major Market Sub-Segment, 2016 and 2021	27
Table 2.4: Summary of Asian Professional POCT Markets by Major Market Sub-Segment, 2016 and 2021	28
Table 2.5: Summary of ROW Professional POCT Markets by Major Market Sub-Segment, 2016 and 2021	29
Table 2.6: Worldwide Distribution of IVD Testing, 2016	36
Table 2.7: Top 13 Country IVD Testing Markets, 2016	37
Table 2.8: Company Market Share for IVD Testing Markets, 2016	38
Table 2.9: Competitive Landscape for POC Diagnostic Testing	42
Table 3.1: Total Global POCT Market, 2008-2021	46
Table 3.2: Global Revenues for POC Blood Glucose Monitoring Systems, 2014-2021	47
Table 3.3: Global Revenues for POC Blood Gas and Electrolyte Analyzers, 2014-2021	47
Table 3.4: Global Revenues for POC Rapid Coagulation Analyzer Systems, 2014-2021	48
Table 3.5: Global Revenues for POC Cardiac Marker Devices, 2014-2021	48
Table 3.6: Global Revenues for POC Substance/Drug Abuse Testing Device Market, 2014-2021	49
Table 3.7: Global Revenues for POC Infectious Disease Testing Devices Market, 2014-2021	49
Table 3.8: Global Revenues for POC Urine Strip Testing Products Market, 2014-2021	50
Table 3.9: Global Revenues for POC Pregnancy Testing Devices Market, 2016-2021	50
Table 3.10: Global Revenues for POC Fecal Occult Testing Devices Market, 2014-2021	51
Table 3.11: Global Revenues for POC Cholesterol Testing Products Market, 2014-2021	51
Table 3.12: Global POCT Market Share Analysis, 2016	52
Table 3.13: Worldwide POCT Market Size by Geographic Location, 2008-2021	52
Table 3.14: Worldwide Distribution of Professionally Administered POCT, 2016	53
Table 4.1: U.S. Revenues for POCT Market, 2015-2021	54
Table 4.2: U.S. Revenues for POC Blood Glucose Monitoring Systems, 2014-2021	55
Table 4.3: U.S. Revenues for POC Blood Gas and Electrolyte Analyzers, 2014-2021	55
Table 4.4: U.S. Revenues for POC Rapid Coagulation Analyzer Systems, 2014-2021	56
Table 4.5: U.S. Revenues for POC Cardiac Marker Devices, 2014-2021	56
Table 4.6: Market Share of U.S. POCT Cardiac Marker Market, 2016	57
Table 4.7: U.S. Revenues for POC Substance/Drug Abuse Testing Device Market, 2014-2021	57
Table 4.8: U.S. Revenues for POC Infectious Disease Testing Devices Market, 2014-2021	58
Table 4.9: U.S. Revenues for POC Urine Strip Testing Products Market, 2014-2021	58
Table 4.10: U.S. Revenues for POC Pregnancy Testing Devices Market, 2014-2021	59
Table 4.11: U.S. Revenues for POC Fecal Occult Testing Devices Market, 2014-2021	59
Table 4.12: U.S. Revenues for POC Cholesterol Testing Products Market, 2014-2021	60
Table 4.13: U.S. POCT Market Share Analysis, 2016	60
Table 4.14: Summary of U.S. POCT Markets by Market Segment, 2016	61
Table 5.1: Models of Public-Private Partnership in Hospital Provision	65
Table 5.2: European Revenues for POCT Market, 2014-2021	68
Table 5.3: French Revenues for POCT Systems, 2008-2018	69
Table 5.4: German Revenues for POCT Systems, 2008-2018	70
Table 5.5: Italian Revenues for POCT Systems, 2008-2018	70

Table 5.6: Spanish Revenues for POCT Systems, 2008-2018	71
Table 5.7: U.K. Revenues for POCT Systems, 2008-2018	71
Table 5.8: Benelux Revenues for POCT Systems, 2008-2018	72
Table 5.9: Scandinavian Revenues for POCT Systems, 2008-2018	72
Table 5.10: Rest-of-Europe Revenues for POCT Systems, 2008-2018	73
Table 5.11: European Revenues for POC Blood Glucose Monitoring Systems, 2014-2021	74
Table 5.12: European Revenues for POC Blood Gas and Electrolyte Analyzers, 2014-2018	74
Table 5.13: European Revenues for POC Rapid Coagulation Analyzer Systems, 2014-2021	75
Table 5.14: European Revenues for POC Cardiac Markers, 2014-2021	77
Table 5.15: European Revenues for POC Substance/Drug Abuse Testing Market, 2014-2021	77
Table 5.16: European Revenues for POC Infectious Disease Testing Market, 2014-2021	78
Table 5.17: European Revenues for POC Urine Strip Testing Products Market, 2014-2021	79
Table 5.18: European Revenues for POC Pregnancy Testing Market, 2014-2021	79
Table 5.19: European Revenues for POC Fecal Occult Blood Testing Market, 2014-2021	80
Table 5.20: European Revenues for POC Cholesterol Testing Products Market, 2014-2021	80
Table 5.21: European Market Share Analysis, 2016	81
Table 6.1: Summary Analysis of Japanese, Chinese and Indian POCT Market, 2008-2018	82
Table 6.2: Summary Analysis of Japanese, Chinese and Indian Revenues for POC Blood Glucose Monitoring Systems, 2008-2018	83
Table 6.3: Summary Analysis of Japanese, Chinese and Indian Revenues for POC Blood Gas and Electrolyte Analyzers, 2008-2018	83
Table 6.4: Summary Analysis of Japanese, Chinese and Indian Revenues for POC Rapid Coagulation Analyzer Systems, 2008-2018	84
Table 6.5: Summary Analysis of Japanese, Chinese and Indian Revenues for POC Cardiac Marker Devices, 2008-2018	84
Table 6.6: Summary Analysis of Japanese, Chinese and Indian Revenues for POC Substance/Drug Abuse Testing Device Market, 2008-2018	85
Table 6.7: Summary Analysis of Japanese, Chinese and Indian Revenues for POC Infectious Disease Testing Devices Market, 2008-2018	85
Table 6.8: Summary Analysis of Japanese, Chinese and Indian Revenues for POC Urine Strip Testing Products Market, 2008-2018	86
Table 6.9: Summary Analysis of Japanese, Chinese and Indian Revenues for POC Pregnancy Testing Devices Market, 2008-2018	86
Table 6.10: Summary Analysis of Japanese, Chinese and Indian Revenues for POC Fecal Occult Testing Devices Market, 2008-2018	87
Table 6.11: Summary Analysis of Japanese, Chinese and Indian Revenues for POC Cholesterol Testing Products Market, 2008-2018	87
Table 6.12: Summary Analysis of Japanese, Chinese and Indian Market Shares, 2016	88
Table 6.13: Japanese Population and Aging Demographics Forecast, 2000-2050	89
Table 6.14: Japanese Revenues for POCT Market, 2008-2018	90
Table 6.15: Indian Revenues for POCT Market, 2008-2018	93
Table 6.16: Chinese Revenues for POCT Market, 2008-2018	95
Table 7.1: Summary Analysis of ROW POCT Market, 2014-2021	101
Table 7.2: Summary Analysis of ROW Revenues for POC Blood Glucose Monitoring Systems, 2008-2021	102
Table 7.3: Summary Analysis of ROW Revenues for POC Blood Gas and Electrolyte Analyzers, 2008-2021	103
Table 7.4: Summary Analysis of ROW Revenues for POC Rapid Coagulation Analyzer Systems, 2008-2021	103
Table 7.5: Summary Analysis of ROW Revenues for POC Cardiac Marker Devices, 2008-2021	104
Table 7.6: Summary Analysis of ROW Revenues for POC Substance/Drug Abuse Testing Device Market, 2008-2021	104
Table 7.7: Summary Analysis of ROW Revenues for POC Infectious Disease Testing Devices Market, 2008-2021	105
Table 7.8: Summary Analysis of ROW Revenues for POC Urine Strip Testing Products Market, 2008-2021	105

Table 7.9: Summary Analysis of ROW Revenues for POC Pregnancy Testing Devices Market, 2008-2021	106
Table 7.10: Summary Analysis of ROW Revenues for POC Fecal Occult Testing Devices Market, 2008-2021	106
Table 7.11: Summary Analysis of ROW Revenues for POC Cholesterol Testing Products Market, 2008-2021	107
Table 7.12: Summary Analysis of ROW Market Shares, 2016l	107
Table 7.13: Summary Analysis of Argentinian Revenues for POCT Products Market, 2008-2018	108
Table 7.14: Summary Analysis of Australian Revenues for POCT Products Market, 2008-2018	108
Table 7.15: Summary Analysis of Brazilian Revenues for POCT Products Market, 2008-2018	109
Table 7.16: Summary Analysis of Canadian Revenues for POCT Products Market, 2008-2018	110
Table 7.17: Summary Analysis of Russian Revenues for POCT Products Market, 2008-2018	110
Table 7.18: Summary Analysis of Middle East Revenues for POCT Products Market, 2008-2018	111
Table 7.19: Summary Analysis of African Revenues for POCT Products Market, 2008-2018	112
Table 7.20: Summary Analysis of Asia (Other) Revenues for POCT Products Market, 2008-2018	113
Table 7.21: Summary Analysis of Latin America (Other) Revenues for POCT Products Market, 2008-2018	116
Table 8.1: Selected POC Blood Glucose Meters Marketed for Professional Use, 2017	126
Table 8.2: POC HbA1c Testing Devices and Assays on the Market, 2017	135
Table 8.3: Global Revenues for Total Professional Blood Glucose Monitoring (Central Laboratory Testing and Hospital POC and POL), 2013-2019	141
Table 8.4: SWOT Analysis: Summary of Strengths, Weaknesses, Opportunities and Threats of the Glucose Point of Care Market	142
Table 8.5: Global Share of Glucose Testing Market by Company, 2016	144
Table 8.6: Selected POC Blood Gas and Electrolyte Analyzers, 2017	155
Table 8.7: Market Share of Blood Gas and Electrolyte POCT Diagnostic Testing Companies Worldwide, 2016	161
Table 8.8: SWOT Analysis: Summary of Strengths, Weaknesses, Opportunities and Threats in the Blood Gas and Electrolyte POC Market	164
Table 8.9: Hospital Locations of Point of Care Coagulation Testing	166
Table 8.10: Selected POC Rapid Coagulation Analyzers, 2017	172
Table 8.11: Connectivity Modes for Leading Coagulation POCT Analyzers	181
Table 8.12: Market Share for Coagulation POCT Diagnostic Testing Companies, 2016	183
Table 8.13: Drivers for Point of Care Coagulation Testing	185
Table 8.14: Barriers for Point of Care Coagulation Testing	186
Table 8.15: SWOT Analysis: Summary of Strengths, Weaknesses, Opportunities and Threats in the Coagulation POC Market	187
Table 8.16: Selected POC Cardiac Biomarker Tests, 2017	197
Table 8.17: Market Share of Cardiac Marker POCT Diagnostic Testing Companies Worldwide, 2016	206
Table 8.18: POC Cardiac Marker Testing Market: Market Drivers Ranked in Order of Impact	208
Table 8.19: POC Cardiac Marker Testing Market: Market Restraints Ranked in Order of Impact	209
Table 8.20: SWOT Analysis: Summary of Strengths, Weaknesses, Opportunities and Threats in the Cardiac Marker POC Market	211
Table 8.21: Drug Testing Needs Tier I for Rapid Serum POCT in the Emergency Department	217
Table 8.22: Stat Urine Testing Drug Recommendations	217
Table 8.23: Selected POC Substance/Drug Abuse Testing Devices, 2017	222
Table 8.24: Selected POC Pregnancy Testing Devices, 2017	233
Table 8.25: Selected POC Fecal Occult Testing Devices, 2017	238
Table 8.26: ColoCARE Fecal Occult Blood Test	239
Table 8.27: SWOT Analysis: Summary of Strengths, Weaknesses, Opportunities and Threats in the Fecal Occult Blood POC Market	245
Table 8.28: Selected POC Infectious Disease Testing Devices and Assays, 2017	251
Table 8.29: Influenza Diagnostic Rapid Tests	265
Table 8.30: Selected POC Urine Strip Testing, 2017	292
Table 8.31: Selected POC Cholesterol Testing Devices, 2017	296
Table 8.32: AmniSure	310

Table 8.33: Competitive Factors Related to HIV Tests	316
Table 8.34: Global POCT Market for Rapid HIV Testing, 2011-2021	317
Table 8.35: Global POCT Share of HIV Testing Market, 2016	318
Table 8.36: Rapid HIV Immunoassay Tests, 2017	319
Table 9.1: POCT1-Compliant Connectivity POC Instruments	334
Table 9.2: POCT Clinical Outcomes in Diabetic Ketoacidosis	336
Table 9.3: POCT in Three Hospitals—Cost Analysis with Labor Included	339
Table 9.4: POCT versus Central Lab—Cost Analysis for Glucose Testing	339
Table 11.1: Common Genotype Techniques	369
Table 12.1: Applications for Wireless LAN Technology	375
Table 12.2: Customized Reports Must Support CAP and JCAHO Requirements	378
Table 14.1: Test Menu and TAT for ED	419
Table 14.2: Top Reasons Why POC Cardiac Marker Testing is Implemented in the ED	420
Table 14.3: Key Areas and Metrics that Hospitals Measure to Assess Efficiency of ED	421

SAMPLE

1. Overview

Point of care testing (POCT) enables rapid diagnostic tests to be performed while the patient is at the point of care (POC) facility where results can be obtained immediately rather than waiting hours or even days for outside lab results to arrive. POCT covers: blood glucose testing, blood gas and electrolytes analysis, rapid coagulation testing, rapid cardiac markers diagnostics, drugs of abuse screening, urine strips testing, pregnancy testing, fecal occult blood analysis, hemoglobin diagnostics, infectious disease testing and cholesterol screening. This TriMark Publications report describes the professional POC testing segment of the diagnostic market (as opposed to at-home testing and other venues that are not in the hands of healthcare professionals).

The two most important areas where such tests are measured for immediate results in a POC setting are hospital emergency rooms and critical-care clinics. The third place where these tests are frequently measured in what is characterized as a near-patient setting is in physician's office labs (POLs). Other testing areas of interest for these analytes are satellite labs, critical-care units, neonatal intensive-care units (NICUs), intensive-care units (ICUs) and home testing locations. Home testing is not covered in this report.

This report also examines the subsections of each POC market segment, including: glucose, blood gases, coagulation, cardiac markers, drugs of abuse, infectious disease and many others. Additionally, rapid detection of infectious pathogens (methicillin-resistant *Staphylococcus aureus* [MRSA], herpes simplex, avian flu, West Nile virus [WNV] and typhoid) is discussed.

This examination of POCT focuses on the POC segments in important worldwide markets, such as the U.S., Japanese, European, Asian and Rest-of-the-World (ROW) markets. An extensive review of POCT in this report includes the market for diagnostic equipment and supplies as well as the market for screening reagents and instruments for analysis of individual components in blood, serum, urine and other body fluids. This report defines the dollar volume of sales, for both worldwide and U.S. markets, and it analyzes the factors that influence the size and the growth of the individual market segments. The market estimates have been factored to reflect the professional healthcare use, which is of most interest to diagnostic companies.

Most of the companies known to be developing instruments and reagents for the clinical POC market are examined in this study. Each company is discussed in depth with a section on the history of the company, the product line, a business and marketing analysis and a subjective commentary of the position of the company in its market.

1.1 About This Report

A review of analytes that are related to the chemical and cellular constituents of blood, plasma or serum at the point of care of the patient is addressed in this study. The two most important areas where such tests are measured are in the hospital and the clinic environments (the emergency department and the critical-care section). Another important place where these tests are measured is in POLs. Newer testing areas of interest for these analytes are satellite labs, corporate facilities, law enforcement agencies and home testing locations. This report's emphasis is on companies that are actively developing and marketing clinical laboratory instrumentation, reagents and supplies for performing clinical diagnostic tests in the near-patient environment. The main objectives of this analysis are:

- For the general point of care testing market:
 - The size of the market and distribution between different market segments.
 - The expected growth over the next five years within each market segment.
 - A comprehensive overview of the main POCT players. What kind of instruments do they have and what is range of analysis?
 - Which analysis in POCT is expected to experience exceptional growth going forward?
- Identifying viable technology drivers through a comprehensive look at platform technologies for POCT.
- Understanding the different sectors of POCT, looking at the hospital market segment and, separately, at a description of the instruments, reagents and supplies marketed by major companies in each segment.
- Obtaining a complete understanding of the individual POC tests, from their basic principles to their clinical applications.

- Discovering feasible market opportunities by identifying high-growth applications in different analytical diagnostic areas, emphasizing the biggest and expanding markets.
- Focusing on global industry development through an in-depth analysis of the major world markets for POC technology, including growth forecasts.
- Presenting POCT market figures regarding the market's current value, market projections, market share, key players and sector growth rates. This information is the most currently available data derived from the global diagnostic industry.

This study contains:

- A detailed analysis of recent trends in the professional POC marketplace.
- In-depth profiles of the leading companies with POC tools and technologies.
- A forecast for the professional POC market and diagnostic segments thereof.
- Views and predictions on the POC industry from leading industry experts.
- An analysis of potential new POC applications in the clinical sector.
- Market predictions and trends analysis concerning U.S. expenditures on POC solutions.
- Projections of POC market sizes for European and Asian markets.
- Projections for future applications of molecular diagnostic tests in POC-related screening.
- Analysis of commercial POC business strategies.
- The latest news and mergers and acquisitions (M&As) developments in the POC marketplace.
- A comprehensive overview of and insight into POC business strategies.
- An in-depth examination of the subsections of each market segment, including the POLs and clinic testing.

Analysis includes charts and graphs measuring product growth and trends within the marketplace. Company-specific information, including sales figures, product pipeline status and research and development (R&D) trends, is provided. This review will also:

- Assess POC market drivers and bottlenecks from medical and scientific community perspectives.
- Discuss the potential benefits of POC for various sectors of the medical and scientific community.
- Establish the current total market size and future growth of the POC market and analyze the current size and growth of individual segments.
- Provide current and forecasted market shares by company.
- Discuss profit and business opportunities by segment.
- Provide strategic recommendations for near-term business opportunities.
- Assess current commercial uses of the POC market.

The following questions will also be addressed in this analysis:

- What are the near-term business opportunities in the POCT market?
- What are the current and forecasted POCT market sizes in the U.S., the European Union (E.U.), Japan and other key country markets?
- What are the business models currently used by companies in the POCT market?
- How will stakeholders like manufacturers, regulators, physicians and patients influence this market?
- What are the drivers and restraints influencing the POCT market?
- What are the important technologies used in POCT?
- Who holds the proprietary rights to the POCT market technology platforms?
- In the U.S., Japan and the E.U., what regulatory processes apply to POCT technologies?
- How will new POC technologies change diagnostic screening testing paradigms?
- How will new POC technologies reduce healthcare expenditures and affect R&D spending?
- What are the newest instruments introduced into the professional POC market.

The report contains:

- A comprehensive overview of the several categories of POC technology platforms that are or will be revolutionizing the use of diagnostic tests in hospitals.
- A chapter on each of the important POC categories and applications (glucose, cardiac markers, HIV, respiratory diseases, and more...).
- Full descriptions of the technologies involved and how they differ from existing and emerging technologies.
- Analysis of the technological approaches undertaken by various competitors, as well as industry and end-user responses to these products.
- Regulatory issues and legislation affecting the use and marketing of POC products.
- Market forecasts for each category of product, including profiles of selected competitors.

1.2 Scope of the Report

The POCT diagnostic product markets in the U.S., Japan and Europe—the world’s three largest analytical markets—are the focus of this study. Analysis of the diagnostic and POC activity of a number of other smaller country markets is also included. Primary attention is paid to the clinical market segment and, separately, to the instruments, reagents and supplies marketed by major companies in this segment. Market size, growth rates and market components for instruments, reagents, controls and consumables used in this area are also analyzed. In general, the non-professional (home care) market for self-testing is considered an entirely different market from professional (hospitals, clinics and doctor’s offices) testing and is not considered in this report in any detailed way. Other related areas, *e.g.*, infant jaundice evaluation, anthrax detection, homeland defense testing, bovine spongiform encephalopathy (BSE, *i.e.*, Mad Cow Disease), tuberculosis and food pathogens, are also discussed.

This report focuses on the “point of care” market. In this context, this phrase means “professional” testing, which extends beyond the hospital ER to doctor’s offices and other medical facilities where trained personnel perform the tests. In the context of this report, and by general agreement within the diagnostics sector, this will exclude so called “home testing”. Over █% of this type of testing is used for glucose measurements. More information on self-testing markets is available in a TriMark report entitled *World Glucose Self-Testing Markets*.

The reader should consult other TriMark Publications reports at www.trimarkpublications.com for detailed discussions of important individual market segments related to the POCT market such as *POC Diagnostic Sector Testing Trends, Blood Glucose Testing and Diabetes Management*, and *Women’s Health Diagnostic Testing*.

1.3 Objectives

The key objective of this study is to conduct a comprehensive review of the POCT market with particular emphasis on emerging trends in equipment and supplies using screening reagents and instruments for analysis of individual components in tissue samples, blood, serum or plasma. Also examined are the sub-segments of each market segment, including physician’s office labs, specialty labs (*e.g.*, NICUs) and critical-care laboratories. In addition, this report reviews a number of institutions using these forms of POCT and includes a discussion of the factors that influence their purchasing decisions. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the POC market.

1.4 Methodology

The author of this report holds a Ph.D. in biochemistry from the University of Minnesota and has had post-doctoral experience at the University of Connecticut School of Medicine. He has taught at Quinnipiac University and the Tufts School of Medicine and has been a senior scientist at Pfizer Pharmaceutical Laboratories in drug development. He also has many decades of experience in science writing and as a medical industry analyst. He has over 30 years of experience in laboratory testing and instrument and reagent development technology as a licensed clinical laboratory director, as well as extensive experience in senior-level management positions in biotech and medical service companies.

Company-specific information is obtained mainly from industry trade publications, academic journals, news and research articles, press releases and corporate websites as well as from annual reports for publicly-held firms. Additional sources of information include non-governmental organizations (NGOs) such as the World Health Organization (WHO) and governmental entities such as the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Where possible and practicable, the most recent data available have been used.

Some of the statistical information was taken from Biotechnology Associates' databases and from TriMark's private data stores. The information in this study was obtained from sources that we believe to be reliable, but we do not guarantee the accuracy, adequacy or completeness of any information or omission or the results obtained from the use of such information. Key information from the business literature was used as a basis to conduct dialogue with and obtain expert opinion from market professionals regarding commercial potential and market sizes. Senior managers from major company players were interviewed for part of the information in this report.

Primary Sources

TriMark collects information from hundreds of Database Tables and many comprehensive multi-client research projects, as well as from Sector Snapshots that it publishes annually. TriMark extracts relevant data and analytics from its research as part of this data collection.

Secondary Sources

TriMark uses research publications, journals, magazines, newspapers, newsletters, industry reports, investment research reports, trade and industry association reports, government-affiliated trade releases and other published information as part of its secondary research materials. The information is then analyzed and translated by the Industry Research Group into a TriMark study. The Editorial Group reviews the complete package with product and market forecasts, critical industry trends, threats and opportunities, competitive strategies and market share determinations.

TriMark Publications Report Research and Data Acquisition Structure

The general sequence of research and analysis activity prior to the publication of every report includes the following items:

- Completing an extensive secondary research effort on an important market sector, including gathering all relevant information from corporate reporting, publicly-available databases, proprietary databases, direct meetings and personal interviews with key personnel.
- Formulating a study outline with the assigned writer, including the following:
 - Market and product segment grouping and evaluating their relative significance.
 - Key competitors' evaluations, including their relative positions in the business and other relevant facts to prioritize diligence levels and assist in designing a primary research strategy.
 - End-user research to evaluate analytical significance in market estimation.
 - Supply chain research and analysis to identify any factors affecting the market.
 - New technology platforms and cutting-edge applications.
- Identifying the key technology and market trends that drive or affect these markets. Assessing the regional significance for each product and market segment for proper emphasis of further regional/national primary and secondary research.
- Launching a combination of primary research activities, including two levels of questionnaires and executive-direct focused, company-specific and region-specific communications to qualified and experienced senior executives worldwide.

- Completing a confirmatory primary research assessment of the report's findings with the assistance of Expert Panel Partners from the industry being analyzed.

The information is then analyzed and translated by the Industry Research Group into a TriMark study. The Editorial Group reviews the complete package with product and market forecasts, critical industry trends, threats and opportunities, competitive strategies and market share determinations.

Finally, before publication, each market report is reviewed by a fact checker, and editor and a proof reader. The final copy is ultimately released by the Editor-in-Chief and management.

1.5 Executive Summary

The professional POCT market sub-segment was valued at \$ [REDACTED] in [REDACTED]. It is estimated that the global POCT market will exhibit a compound annual growth rate (CAGR) of [REDACTED] % between [REDACTED] and [REDACTED] to \$ [REDACTED].

The report provides a summary of the global professional POCT market divided into individual major market sub-segments, with market values for [REDACTED] and market projections to [REDACTED]. With any growth rate estimate, glucose testing remains the leading point of care testing global segment, accounting for [REDACTED] % of global near patient testing by [REDACTED]. Excluding glucose testing, only rapid cardiac markers rises to >\$ [REDACTED] in POC testing by [REDACTED], accounting for an estimated [REDACTED] % of total testing by [REDACTED].

Despite budget pressures on hospitals, point of care testing will continue to grow at a rate larger than central lab testing, powered by continuing trends for adoption and use of these platforms across disciplines, notably cardiac markers, coagulation and infectious disease. As such, several diagnostic companies have scheduled advanced multiplexing platforms in their development pipelines, including a broad range of immunoassays and molecular tests.

The U.S. is recognized as the largest single country market for POCT products by [REDACTED]. In [REDACTED], the U.S. POCT market was valued at \$ [REDACTED]. TriMark estimated that the U.S. POCT market would exhibit a CAGR of [REDACTED] % between [REDACTED] and [REDACTED] to \$ [REDACTED]. In the U.S. market, glucose testing remains the leading point of care testing segment used by hospital professionals, accounting for [REDACTED] % of near patient testing by [REDACTED], decreasing to [REDACTED] % in [REDACTED]. Excluding glucose testing, no rapid testing segments rise to the \$ [REDACTED] level in U.S. POC testing by [REDACTED]. Glucose testing is still king. U.S. Point of Care testing by professionals for infectious diseases is projected to grow at [REDACTED] % over the forecast period; accounting for an estimated [REDACTED] % of total testing by [REDACTED]; compared with its [REDACTED] % share of U.S. testing in [REDACTED]. Infectious disease testing at POCT will emerge as the third largest segment by [REDACTED], surpassing the blood gas & electrolytes sector. Infectious disease testing is rising fast.

TriMark has determined that Europe represents the largest regional market for POCT products in [REDACTED], but falls to second place versus the U.S. in [REDACTED]. In [REDACTED], the European POCT market was valued at \$ [REDACTED]. TriMark estimated that the European POCT market would exhibit a CAGR of [REDACTED] % between [REDACTED] and [REDACTED] to \$ [REDACTED]. Germany is widely recognized as the largest single market for both IVD and POCT products within Europe. The German POCT market in [REDACTED] was valued at \$ [REDACTED]. The hospital and healthcare services structure in Germany makes it particularly suitable for the use of POCT products, leading to the higher percentage of POCT products as part of the IVD market.

In the European professional POCT market, glucose testing remains the leading point of care testing segment, accounting for [REDACTED] % of near patient testing by [REDACTED], decreasing to [REDACTED] % in [REDACTED]. Excluding glucose testing, no rapid testing segments rise to the \$ [REDACTED] level in Europe. Glucose testing is still king, even in Europe. In fact, this dominance for glucose testing is predominantly the result of weaker sales in all other segments of POCT, unlike the U.S. market where several segments are projected to grow by double digits (cardiac markers & infectious disease).

European Point of Care testing by professionals for infectious diseases is projected to grow at [REDACTED] % over the forecast period; accounting for an estimated [REDACTED] % of total testing by [REDACTED]. Infectious disease testing at POCT will emerge as the second largest segment in the European market by [REDACTED].

Asia (which includes Japan, China and India for the purposes of this report) represents a major market, but there are significant differences in growth rates for each of the individual countries. The POCT segment represented an estimated █% of the Asian IVD market in █. In █, the POCT market for Japan, China and India (referred to as the Asian POCT market in this report) was \$█. TriMark estimated that the Asian POCT market would exhibit a CAGR of █% between █ and █.

The Japanese POCT market has slowed recently and is expected to see a CAGR of █%; it is estimated to have been valued at \$█ in █. In contrast, the emerging markets of India and China are exhibiting higher CAGRs of █% and █%, respectively, between █ and █, and are valued at \$█ and \$█ in █, respectively.

The report also provides a summary of the Asian POCT market segmented by individual major market sub-segment with market values for █ and market projections to █.

Although the ROW segment represents the geographic region with the smallest revenue, it is nevertheless a moderate growth opportunity (CAGR █%), and includes the emerging markets of Brazil and Russia. Included in this regional analysis are the Middle East, Africa, other Asian countries, Australia, Canada and other Latin American countries such as Mexico and Argentina.

As a result of the analysis carried out during the preparation of this report, TriMark has concluded that the professional handled POCT market for the ROW was valued at \$█ in █. It is predicted that the market for professional POCT products in the ROW will be valued at \$█ by █ (a CAGR of █% between █ and █). The underlying market fundamentals remain strong given the rising number of people with diabetes globally, especially in Asia and the ROW.

Roche, Alere [to be possibly acquired by Abbott] and Abbott Laboratories are the three largest suppliers of POCT devices throughout the world and collectively comprise an estimated █% of the global market. Although other companies, such as Nova, are becoming increasingly focused on POCT, increasing their product expansion and collaboration efforts to gain market share, the market remains extremely fragmented. Alere has sought to improve its market position through its acquisitions of companies like Biosite, Axis-Shield and its collaborations with SureStat and Chembio. Alere's HIV market share, on the other hand, could erode with the entry of Roche and Orasure and the advent of oral HIV tests. Nova Biomedical is becoming a reliable player with its new POCT platform. POCT dynamics are changing rapidly, and smaller players are poised to deliver value with their innovative platforms and growing test menus. The market has been driven by a transition to fully-automated systems, real-time amplification, connectivity platforms and growing test development for POC platforms.

TriMark estimates that future growth will stem from emerging applications like genotyping for identifying drug-resistant strains; bioterrorism; testing applications within infectious disease like Influenza and HIV; and disease diagnostics and prognostic assays for disease applications like sepsis, cardiovascular disease (CHF) and coagulation testing. The industry consolidation is significant, as larger players like Abbott, with the acquisition of Alere, want to move into faster-growing markets to expand their product offerings and/or geographical reach. Larger, established diagnostic players like Roche are eager to build out and extend their molecular diagnostic franchises for point of care technology and are willing to pay premium prices for good technology.

Market growth will be paced by substantial gains in the cardiac markers market (primarily beta-natriuretic-peptide (BNP) testing), coagulation, infectious disease testing and continued moderate growth in the clinical chemistry sub-segment—the largest in the POCT market. The later constellation of routine tests, now dominated by central lab testing (ALT, AST, BUN, creatinine, etc.), will eventually migrate completely to near patient testing.

- The value of the global professional POC blood glucose analysis systems market in █ was \$█. By the end of the forecast period in █, it is predicted that this market will have increased in value to \$█ (with an average CAGR of █% from █ to █). Industry experts expect that the U.S. and Europe POC blood glucose testing market revenues will continue to be negatively impacted by pricing pressure and weak volume growth. In addition, the U.S. market may be affected by a proposed tightening of performance standards to address the limitations of some current blood glucose meters. However, the

underlying market fundamentals remain strong given the rising number of people with diabetes globally, especially in Asia and the ROW.

- The value of the global POC blood gas and electrolyte analysis systems market in [REDACTED] was \$ [REDACTED]. By the end of the forecast period in [REDACTED], it is predicted that this market will have increased in value to \$ [REDACTED] with an average CAGR of [REDACTED]% from [REDACTED] to [REDACTED].
- The value of the global POC rapid coagulation analyzers systems market increased to an estimated \$ [REDACTED] by [REDACTED]. By the end of the forecast period in [REDACTED], it is predicted that the market will have increased in value to \$ [REDACTED] (with an average CAGR of [REDACTED]% from [REDACTED] to [REDACTED]).
- The value of the global POC cardiac marker analysis device market increased to an estimated \$ [REDACTED] by [REDACTED]. By the end of the forecast period in [REDACTED], it is predicted that the market will have increased in value to \$ [REDACTED] (with an average CAGR of [REDACTED]% from [REDACTED] to [REDACTED]).
- The value of the global POC substance/drug abuse testing devices market increased to an estimated \$ [REDACTED] by [REDACTED]. By the end of the forecast period in [REDACTED], it is predicted that the market will have increased in value to \$ [REDACTED] (with an average CAGR of [REDACTED]% from [REDACTED] to [REDACTED]).
- The global POC infectious disease testing devices market increased to an estimated \$ [REDACTED] by [REDACTED]. By the end of the forecast period in [REDACTED], it is predicted that the market will have increased in value to \$ [REDACTED] (with an average CAGR of [REDACTED]% from [REDACTED] to [REDACTED]).
- The value of the global POC urine strip testing products market increased to an estimated \$ [REDACTED] by [REDACTED]. By the end of the forecast period in [REDACTED], it is predicted that the market will have increased in value to \$ [REDACTED] (with an average CAGR of [REDACTED]% from [REDACTED] to [REDACTED]).
- The value of the global POC pregnancy testing devices market increased to an estimated \$ [REDACTED] by [REDACTED]. By the end of the forecast period in [REDACTED], it is predicted that the market will have increased in value to \$ [REDACTED] (with an average CAGR of [REDACTED]% from [REDACTED] to [REDACTED]).
- The value of the global POC fecal occult products market increased to an estimated \$ [REDACTED] by [REDACTED]. By the end of the forecast period in [REDACTED], it is predicted that the market will have increased in value to \$ [REDACTED] (with an average CAGR of [REDACTED]% from [REDACTED] to [REDACTED]).
- The value of the global POC cholesterol testing products market increased to an estimated \$ [REDACTED] by [REDACTED]. By the end of the forecast period in [REDACTED], it is predicted that the market will have increased in value to \$ [REDACTED] (with an average CAGR of [REDACTED]% from [REDACTED] to [REDACTED]).
- The value of the global POC HIV testing products market increased to an estimated \$ [REDACTED] by [REDACTED]. By the end of the forecast period in [REDACTED], it is predicted that the market will have increased in value to \$ [REDACTED] (with an average CAGR of [REDACTED]% from [REDACTED] to [REDACTED]).